Without Cutting DNA, Rewriting RNA Ends: CRISPR Makes Prostate Cancer Visible Again

Prostate cancer is often regarded as a “cold tumor” that is difficult to treat with immunotherapy: it is not that immune cells completely lack the ability to kill, but that cancer cells are poor at displaying antigens that can be recognized. A study published in *Nature Biomedical Engineering* proposes another path—not directly cutting DNA, but adjusting the processing of messenger RNA ends so that tumors are exposed to immune surveillance again.

The team’s 3′UTRCES platform uses catalytically inactive Cas13 as a programmable targeting tool, targeting RNA rather than the genome. The researchers found that prostate cancer cells prematurely shorten the 3′ untranslated regions of messenger RNAs, increasing the SPSB1 protein; SPSB1 then promotes the ubiquitination and degradation of major histocompatibility complex class I (MHC-I), weakening cancer cells’ ability to present antigens to CD8 T cells.

After 3′UTRCES prevented the premature shortening of SPSB1 messenger RNA, SPSB1 protein levels decreased, and MHC-I on the cancer cell surface and antigen presentation were restored. This intervention did not directly alter PD-L1, indicating that it addresses a more upstream “recognition failure” outside the immune checkpoint: even if the immune brakes are released, treatment may still have no target if T cells cannot see the tumor.

The researchers then delivered this RNA-engineering tool using lipid nanoparticles. In syngeneic mouse prostate tumor models, the treatment increased MHC-I-dependent CD8 T-cell infiltration and antitumor cytotoxic activity, and also sensitized tumors that had previously responded poorly to immune checkpoint blockade therapy. Figures in the paper also show that the relevant effects were tested in multiple prostate cancer models, while the accompanying transcriptomic and proteomic data have been deposited in public databases, allowing others to investigate the SPSB1 mechanism.

This work expands the role of CRISPR: it can be used not only to permanently rewrite genes, but also to temporarily control how RNA matures. Compared with cutting DNA, intervention at the RNA level is theoretically more reversible; the research team found no detectable off-target effects in the current analyses, but this does not mean that safety in humans has been established. Potential unintended effects of Cas13 on RNA, immune responses, and the tumor selectivity of lipid nanoparticles still require more comprehensive evaluation.

All current evidence remains limited to cells and mice, and it cannot yet be inferred that patients would achieve equivalent efficacy. In addition to replicating the efficacy and toxicity findings, the next steps must determine whether different prostate cancer subtypes are similarly dependent on SPSB1 and whether the treatment can be delivered reliably to human tumors without interfering with normal tissues. If these hurdles can be overcome, correcting RNA end processing could become a new way to awaken other immunologically cold tumors, rather than merely an experimental breakthrough in prostate cancer.